Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from HBM Holdings Ltd. ( (HK:2142) ).
HBM Holdings Ltd. announced that the China National Intellectual Property Administration upheld its patent for a method of producing fully human heavy chain-only antibodies, following a challenge by Biocytogen Pharmaceuticals. This decision reinforces HBM’s intellectual property rights, allowing the company to continue leveraging its patented technology to develop innovative therapies, which could have significant implications for its market positioning and stakeholders.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a company incorporated in the Cayman Islands, focusing on the biotechnology industry. It specializes in the development of fully human heavy chain-only antibodies (HCAbs) using transgenic animals, aiming to advance transformative therapies in collaboration with global partners.
Average Trading Volume: 11,331,362
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.24B
See more data about 2142 stock on TipRanks’ Stock Analysis page.